At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 760 target
Drug / intervention
Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumabdrug
Likely dose
Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab 500mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Platinum-based Chemotherapy With or Without Immune Checkpoint Inhibitors in Patients With EGFR/ALK/ROS1 Sensitive Mutated NSCLC Who Progressed From Previous Tyrosine Kinase Inhibitors (TKI) Therapy
In Brief
A Phase 2 clinical trial evaluating Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab for Non Small Cell Lung Cancer. Currently recruiting, targeting 760 participants across 1 site.
Detailed Summary
The investigators want to evaluate the Efficay and Safety of Platinum-based Chemotherapy with or without immune checkpoint inhibitors for EGFR/ALK/ROS1 Positive NSCLC who Failed from First-Line Standard Treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20232024202520262027
First PostedMar 2022
Enrollment StartApr 2022
TodayJul 2026
Primary CompletionSep 2026
Study CompletionOct 2027
First PostedMar 17, 2022
Enrollment StartApr 1, 2022
Primary CompletionSep 30, 2026
Study CompletionOct 10, 2027
TodayJul 1, 2026
Enrollment to primary: 4.5 yearsPosted 4.3 years agoPrimary completion in 3 months
Interventions
Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumabdrug
Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.